Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants - PubMed (original) (raw)

. 2002 Mar 15;295(5562):2097-100.

doi: 10.1126/science.1068440.

Marusca Capanni, Elena Urbani, Katia Perruccio, Warren D Shlomchik, Antonella Tosti, Sabrina Posati, Daniela Rogaia, Francesco Frassoni, Franco Aversa, Massimo F Martelli, Andrea Velardi

Affiliations

• PMID: 11896281
• DOI: 10.1126/science.1068440

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Loredana Ruggeri et al. Science. 2002.

Abstract

T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.

PubMed Disclaimer

Comment in

• Immunology. A perfect mismatch.
  Kärre K. Kärre K. Science. 2002 Mar 15;295(5562):2029-31. doi: 10.1126/science.1070538. Science. 2002. PMID: 11896262 No abstract available.

Similar articles

• The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
  Bishara A, De Santis D, Witt CC, Brautbar C, Christiansen FT, Or R, Nagler A, Slavin S. Bishara A, et al. Tissue Antigens. 2004 Mar;63(3):204-11. doi: 10.1111/j.0001-2815.2004.00182.x. Tissue Antigens. 2004. PMID: 14989709
• NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.
  Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, Aversa F, Martelli MF, Velardi A. Ruggeri L, et al. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):84-90. doi: 10.1016/j.bcmd.2007.06.029. Epub 2007 Oct 26. Blood Cells Mol Dis. 2008. PMID: 17964828
• Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
  Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z. Chen G, et al. Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28. Eur J Haematol. 2008. PMID: 18573173
• Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
  Strober S. Strober S. Blood Cells Mol Dis. 2008 Jan-Feb;40(1):48-54. doi: 10.1016/j.bcmd.2007.06.019. Epub 2007 Sep 10. Blood Cells Mol Dis. 2008. PMID: 17827036 Review.

Cited by

• Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3.
  Moesta AK, Parham P. Moesta AK, et al. Front Immunol. 2012 Nov 22;3:336. doi: 10.3389/fimmu.2012.00336. eCollection 2012. Front Immunol. 2012. PMID: 23189078 Free PMC article.
• Reduced-intensity conditioned allogeneic SCT in adults with AML.
  Reshef R, Porter DL. Reshef R, et al. Bone Marrow Transplant. 2015 Jun;50(6):759-69. doi: 10.1038/bmt.2015.7. Epub 2015 Mar 2. Bone Marrow Transplant. 2015. PMID: 25730186 Review.
• Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol.
  Koehl U, Brehm C, Huenecke S, Zimmermann SY, Kloess S, Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S, Wunram C, Gardlowski T, Auth E, Tonn T, Seidl C, Meyer-Monard S, Stern M, Passweg J, Klingebiel T, Bader P, Schwabe D, Esser R. Koehl U, et al. Front Oncol. 2013 May 17;3:118. doi: 10.3389/fonc.2013.00118. eCollection 2013. Front Oncol. 2013. PMID: 23730623 Free PMC article.
• Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia.
  Foley B, Ta C, Barnes S, de Jong E, Nguyen M, Cheung LC, Buzzai A, Wagner T, Wylie B, Fernandez S, Cruickshank M, Endersby R, Kees U, Waithman J. Foley B, et al. Clin Transl Immunology. 2020 Jul 16;9(7):e1151. doi: 10.1002/cti2.1151. eCollection 2020. Clin Transl Immunology. 2020. PMID: 32695339 Free PMC article.
• NK cells sense tumors, course of disease and treatments: Consequences for NK-based therapies.
  Fregni G, Perier A, Avril MF, Caignard A. Fregni G, et al. Oncoimmunology. 2012 Jan 1;1(1):38-47. doi: 10.4161/onci.1.1.18312. Oncoimmunology. 2012. PMID: 22720210 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • H1 Connect
  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information